BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

297 related articles for article (PubMed ID: 27888093)

  • 1. Randomized trial of rATg/Daclizumab vs. rATg/Alemtuzumab as dual induction therapy in renal transplantation: Results at 8years of follow-up.
    Ciancio G; Gaynor JJ; Guerra G; Sageshima J; Roth D; Chen L; Kupin W; Mattiazzi A; Tueros L; Flores S; Hanson L; Ruiz P; Vianna R; Burke GW
    Transpl Immunol; 2017 Feb; 40():42-50. PubMed ID: 27888093
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Randomized trial of dual antibody induction therapy with steroid avoidance in renal transplantation.
    Ciancio G; Gaynor JJ; Sageshima J; Guerra G; Zarak A; Roth D; Brown R; Kupin W; Chen L; Hanson L; Tueros L; Ruiz P; Livingstone AS; Burke GW
    Transplantation; 2011 Dec; 92(12):1348-57. PubMed ID: 22027927
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Comparison of alemtuzumab vs. antithymocyte globulin induction therapy in primary non-sensitized renal transplant patients treated with rapid steroid withdrawal.
    Saull HE; Enderby CY; Gonwa TA; Wadei HM
    Clin Transplant; 2015 Jul; 29(7):573-80. PubMed ID: 25711849
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A randomized trial of alemtuzumab versus antithymocyte globulin induction in renal and pancreas transplantation.
    Farney AC; Doares W; Rogers J; Singh R; Hartmann E; Hart L; Ashcraft E; Reeves-Daniels A; Gautreaux M; Iskandar SS; Moore P; Adams PL; Stratta RJ
    Transplantation; 2009 Sep; 88(6):810-9. PubMed ID: 19920781
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Depleting antibody induction in simultaneous pancreas-kidney transplantation: a prospective single-center comparison of alemtuzumab versus rabbit anti-thymocyte globulin.
    Stratta RJ; Rogers J; Orlando G; Farooq U; Al-Shraideh Y; Doares W; Kaczmorski S; Farney AC
    Expert Opin Biol Ther; 2014 Dec; 14(12):1723-30. PubMed ID: 25156622
    [TBL] [Abstract][Full Text] [Related]  

  • 6. 5-year results of a prospective, randomized, single-center study of alemtuzumab compared with rabbit antithymocyte globulin induction in simultaneous kidney-pancreas transplantation.
    Stratta RJ; Rogers J; Orlando G; Farooq U; Al-Shraideh Y; Farney AC
    Transplant Proc; 2014; 46(6):1928-31. PubMed ID: 25131073
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Randomized trial of mycophenolate mofetil versus enteric-coated mycophenolate sodium in primary renal transplant recipients given tacrolimus and daclizumab/thymoglobulin: one year follow-up.
    Ciancio G; Burke GW; Gaynor JJ; Roth D; Sageshima J; Kupin W; Tueros L; Hanson L; Rosen A; Ruiz P; Miller J
    Transplantation; 2008 Jul; 86(1):67-74. PubMed ID: 18622280
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Daclizumab Versus Rabbit Antithymocyte Globulin in High-Risk Renal Transplants: Five-Year Follow-up of a Randomized Study.
    Hellemans R; Hazzan M; Durand D; Mourad G; Lang P; Kessler M; Charpentier B; Touchard G; Berthoux F; Merville P; Ouali N; Squifflet JP; Bayle F; Wissing KM; Noël C; Abramowicz D
    Am J Transplant; 2015 Jul; 15(7):1923-32. PubMed ID: 25707875
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Prospective randomized controlled trial of rabbit antithymocyte globulin compared with IL-2 receptor antagonist induction therapy in kidney transplantation.
    Pilch NA; Taber DJ; Moussa O; Thomas B; Denmark S; Meadows HB; McGillicuddy JW; Srinivas TR; Baliga PK; Chavin KD
    Ann Surg; 2014 May; 259(5):888-93. PubMed ID: 24513787
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A randomized trial of alemtuzumab vs. anti-thymocyte globulin induction in renal and pancreas transplantation.
    Farney A; Sundberg A; Moore P; Hartmann E; Rogers J; Doares W; Jarrett A; Adams P; Stratta R
    Clin Transplant; 2008; 22(1):41-9. PubMed ID: 18217904
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Steroid-free liver transplantation using rabbit antithymocyte globulin and early tacrolimus monotherapy.
    Eason JD; Nair S; Cohen AJ; Blazek JL; Loss GE
    Transplantation; 2003 Apr; 75(8):1396-9. PubMed ID: 12717237
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Alemtuzumab induction in renal transplantation.
    Hanaway MJ; Woodle ES; Mulgaonkar S; Peddi VR; Kaufman DB; First MR; Croy R; Holman J;
    N Engl J Med; 2011 May; 364(20):1909-19. PubMed ID: 21591943
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A randomized trial of thymoglobulin vs. alemtuzumab (with lower dose maintenance immunosuppression) vs. daclizumab in renal transplantation at 24 months of follow-up.
    Ciancio G; Burke GW; Gaynor JJ; Roth D; Kupin W; Rosen A; Cordovilla T; Tueros L; Herrada E; Miller J
    Clin Transplant; 2008; 22(2):200-10. PubMed ID: 18339140
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A randomized 2×2 factorial trial, part 1: single-dose rabbit antithymocyte globulin induction may improve renal transplantation outcomes.
    Stevens RB; Foster KW; Miles CD; Lane JT; Kalil AC; Florescu DF; Sandoz JP; Rigley TH; Nielsen KJ; Skorupa JY; Kellogg AM; Malik T; Wrenshall LE
    Transplantation; 2015 Jan; 99(1):197-209. PubMed ID: 25083614
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The efficacy and safety of alemtuzumab and daclizumab versus antithymocyte globulin during organ transplantation: a meta-analysis.
    Hao WJ; Zong HT; Cui YS; Zhang Y
    Transplant Proc; 2012 Dec; 44(10):2955-60. PubMed ID: 23195005
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A randomized trial of three renal transplant induction antibodies: early comparison of tacrolimus, mycophenolate mofetil, and steroid dosing, and newer immune-monitoring.
    Ciancio G; Burke GW; Gaynor JJ; Carreno MR; Cirocco RE; Mathew JM; Mattiazzi A; Cordovilla T; Roth D; Kupin W; Rosen A; Esquenazi V; Tzakis AG; Miller J
    Transplantation; 2005 Aug; 80(4):457-65. PubMed ID: 16123718
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Induction antibody therapy in renal transplantation using early steroid withdrawal: long-term results comparing anti-IL2 receptor and anti-thymocyte globulin.
    Libório AB; Mendoza TR; Esmeraldo RM; Oliveira ML; Paes FJ; Silva Junior GB; Daher EF
    Int Immunopharmacol; 2011 Nov; 11(11):1832-6. PubMed ID: 21835269
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Alemtuzumab induction for retransplantation after primary transplant with alemtuzumab induction
.
    Descourouez JL; Jorgenson MR; Parajuli S; Mandelbrot DA; Leverson GE; Odorico JS; Redfield RR
    Clin Nephrol; 2020 Feb; 93(2):77-84. PubMed ID: 31670651
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Alemtuzumab induction therapy in highly sensitized kidney transplant recipients.
    Lü TM; Yang SL; Wu WZ; Tan JM
    Chin Med J (Engl); 2011 Mar; 124(5):664-8. PubMed ID: 21518554
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Rabbit antithymocyte globulin (thymoglobulin): a review of its use in the prevention and treatment of acute renal allograft rejection.
    Deeks ED; Keating GM
    Drugs; 2009 Jul; 69(11):1483-512. PubMed ID: 19634926
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.